Asthma

This article records tradition as it has been passed down and reported. Its sources are not yet part of the atlas's verified catalogue.

The word asthma is older than almost anything else in respiratory medicine, but for most of its history it did not mean what it means today. The term comes from an ancient Greek verb, azein, meaning to breathe hard, and Hippocrates was the first to use the word in a medical sense, to describe a symptom, severe shortness of breath, rather than a disease with a cause of its own. He is also credited with linking the condition to a sufferer's environment and occupation, noting connections to work such as metalworking centuries before anyone understood what an occupational trigger was.

Descriptions of breathlessness and wheezing appear earlier still, in ancient Chinese texts from around 2600 BCE and in the Egyptian Ebers Papyrus from around 1500 BCE, though neither used a word that survived into modern medical vocabulary the way Hippocrates' did. What changed only in the final decades of the twentieth century was the underlying model: asthma stopped being treated as a nervous or muscular spasm and came to be understood as a chronic inflammatory disease of the airways, a shift that reshaped how the condition is treated rather than just what it is called.

This article records tradition as it has been passed down and reported. Its sources are not yet part of the atlas's verified catalogue.

The World Health Organization's most recent figures put the global scale of asthma in stark terms: an estimated 363 million people living with the disease in 2023, and 442,000 deaths that year alone, making it the most common chronic disease among children worldwide. The condition itself, inflammation and muscle tightening around the airways that make breathing difficult, is well understood and, for most patients, well controlled with modern treatment.

What the same data makes clear is that control is not evenly available. The World Health Organization reports that most asthma deaths occur in low- and lower-middle-income countries, where under-diagnosis and under-treatment remain a serious barrier, and that as of 2023 potentially life-saving bronchodilators were stocked in public primary health care facilities in less than two-thirds of those countries, with steroid inhalers available in less than half. A disease with a two-and-a-half-thousand-year-old name and a thoroughly modern understanding still kills largely along the fault lines of access rather than the limits of medical knowledge.